Full Press Release Details
GAITHERSBURG, Md., July 6, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report its second quarter 2021 financial results and operational highlights on Thursday, August 5, 2021, following the close of U.S. financial markets. Details of the event and replay are as follows:
| Conference call details: | |
| Date: | August 5, 2021 |
| Time: | 4:30 p.m. U.S. Eastern Time (ET) |
| Dial-in number: | (866) 652-5200 (Domestic) or (412) 317-6060 (International) |
| Webcast: | www.novavax.com/events |
| • Participants will be prompted to request to join the Novavax, Inc. call. | |
| • To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled webcast. | |
| Replay details: | |
| Date: | Available starting at 7:30 p.m. ET, August 5, 2021 |
| Dial-in number: | (877) 344-7529 (Domestic) or (412) 317-0088 (International) |
| Passcode: | 10158313 |
| Webcast: | www.novavax.com/events , until November 12, 2021 |
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.
For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.
Erika Schultz | 240-268-2022
Alexandra Roy | 617-221-9197
Alison Chartan | 240-720-7804
Laura Keenan | 202-709-7521
SOURCE Novavax, Inc.
Related Links
21 %
more press release views with